Japanese encephalitis virus tropism in experimentally infected pigs
© Ricklin et al. 2016
Received: 7 October 2015
Accepted: 1 February 2016
Published: 24 February 2016
Pigs are considered to be the main amplifying host for Japanese encephalitis virus (JEV), and their infection can correlate with human cases of disease. Despite their importance in the ecology of the virus as it relates to human cases of encephalitis, the pathogenesis of JEV in pigs remains obscure. In the present study, the localization and kinetics of virus replication were investigated in various tissues after experimental intravenous infection of pigs. The data demonstrate a rapid and broad spreading of the virus to the central nervous system (CNS) and various other organs. A particular tropism of JEV in pigs not only to the CNS but also for secondary lymphoid tissue, in particular the tonsils with the overall highest viral loads, was observed. In this organ, even 11 days post infection, the latest time point of the experiment, no apparent decrease in viral RNA loads and live virus was found despite the presence of a neutralizing antibody response. This was also well beyond the clinical and viremic phase. These results are of significance for the pathogenesis of JEV, and call for further experimental studies focusing on the cellular source and duration of virus replication in pigs.
Japanese encephalitis virus (JEV) causes an important zoonotic, vector-borne disease present in East Asia, Southeast Asia and Australasia [1, 2]. During JEV epidemics, human infections are widespread but only 0.1–4% of infected individuals develop clinically apparent encephalitis. In the past, the annual incidence of such human cases was in the range from 50 000 to 175 000 [1–3]. Importantly, the mortality of encephalitis cases is as high as 25–30%, and approximately 50% of the surviving patients suffer from neuro-psychiatric sequelae [1, 2]. Therefore, JEV is considered to be the most frequent viral encephalitis associated with fatal outcomes . JEV is currently endemic in large parts of Southeast Asia but similar to other emerging diseases, globalization and climate changes may result in virus emergence in the Western hemisphere. This would cause significant health problems in both the naïve human and animal population. During the last two decades West Nile virus as well as Usutu virus, which both belong to the JEV serocomplex, emerged in Europe, demonstrating that related mosquito-born flaviviruses can spread to and remain in temperate regions . Furthermore, the temperate northern Island of Japan Hokkaido, was affected by JEV epidemics and the virus was shown to overwinter and re-emerge in the same local region .
The ecology of JEV includes a bird-associated wildlife cycle between Culex mosquitoes as vectors and mostly water birds such as egrets and herons as reservoirs. However, it appears that a high level of JE incidence in humans is associated with the presence of pigs as amplifying hosts [1, 2]. Already early studies in the 1950s have demonstrated that pigs are readily infected and develop high level of viremia for several days [7–9]. This fact is an important feature of a pig-associated rural cycle, present mostly in areas with intense pig farming and rice fields, which have been associated with frequent human JE cases .
While clinical symptoms in pigs are mild, humans and horses develop severe disease, and are considered as dead end hosts in which viremia is insufficient to infect feeding mosquitos . High seroprevalence in many other vertebrates, such as dogs, chickens, ducks and reptiles indicate widespread infection by the virus but their role in the ecology of the virus is unclear . Certainly, the high propensity of Culex tritaeniorhynchus to feed on pigs and the high birth rate with rapid turnover of the pig population favor the hypothesis of the pig as being the main amplifying host for JEV leading to human JE cases [1, 2].
During natural infection of pigs in JEV endemic areas, a viremic phase lasting 2–4 days has been described [7, 9, 11]. Clinically, JEV field infections have been associated with increased rates of stillbirth and abortion [6, 12, 13]. Experimental infection of pigs resulted in development of transient fever and depression associated with a non-suppurative encephalitis with viral antigen distributed broadly within the central nervous system (CNS) [14, 15].
Despite this information, the pathogenesis of JEV in pigs remains obscure. Specifically, the localization and kinetics of virus replication associated with viremia have not been studied. Furthermore, data of pig breeds kept in Europe such as Landrace, Large White or Duroc are lacking. The present study demonstrates that after experimental infection of pigs JEV has a strong tropism not only to the CNS but also for secondary lymphoid tissue, in particular the tonsils.
Materials and methods
All animal experiments were performed at biosafety level 3 conditions (BSL3), and under the guidance of the Swiss animal welfare law, approved by the Cantonal ethical committee for animal experiments (BE 118-13). Twelve healthy seven-weeks old swiss large white pigs (seven castrated males and five females) from our specific-pathogen-free (SPF)-breeding facility were used. Animals were housed in groups of ≥3 inside the containment facility of the Institute for Virology and Immunology (IVI) representing a BSL3-Ag facility. Prior to the inoculation experiment, they were allowed 1 week of adaptation to the new environment. After puncturing the jugular vein for a null blood sample all 12 animals were infected with 107 TCID50 of JEV (Nakayama strain, obtained from the National collection of pathogenic viruses, NCPV, Salisbury, UK) in a volume of 2 mL, giving one half of the dose intravenously and the other half intradermally in the neck region. The Nakayama strain represents human genotype III isolate. It was used after two passages on Vero cells (ATCC, Manassas, VA, USA). Considering the low number of pigs possible for this study a high dose was chosen to ensure infection of all animals.
Animals were clinically examined daily, which included measuring body temperature and assessing awareness, appetite, manure excretion, breathing, gait and neurological signs. Daily blood samples and oro-nasal swabs (Sarstedt, Nümbrecht, Germany) were collected from three animals until day 11. Swab samples were drenched in 500 µL medium and the stored at −70 °C until further processing.
To collect organ samples, groups of three pigs were euthanized by electroshock and subsequent exsanguination at days 3, 5, 7 and 11 post infection (pi). Sampling was performed immediately after exsanguination and included collection of blood (for serum and isolation of leukocytes) and organs for quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), virus isolation and histology. The following organs were sampled: cervical lymph node, tonsils, spleen, ileum, bone marrow, thymus, kidney, liver, skeletal muscle and a peripheral nerve (nervus auriculopalpebralis) extracted from the neck region used for intradermal infection. The brain, spinal cord and spinal ganglia were taken out in toto. Of the CNS, the following parts were collected: cervical and sacral spinal cord, brain stem, cerebellum, thalamus, hippocampus, basal nuclei, neocortex frontalis and temporalis, bulbus olfactorius, the meninges and choroid plexus. For histology organ samples were fixed in 4% buffered formalin for 3 days or 4 weeks for brain tissue. Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation as previously described .
Organ samples were taken into 1.5 mL tubes (Sarstedt) containing 500 µL MEM medium (Gibco, Life Technologies, Zug, Switzerland) and were weighed before homogenizing with a BulletBlender® (Next Advanced Inc. Averill Park, NY, USA). Homogenized organs were centrifuged and the supernatant transferred into a new tube to freeze immediately at −70 °C. For qRT-PCR, the samples were thawed and spiked with EGFP RNA as internal control prepared as described , and RNA was extracted using the QIAmp® viral RNA extraction kit (Qiagen AG, Hombrechtikon, Switzerland) according to manufacturer’s instructions. The real-time RT-PCR was performed as published previously , using the SuperScript® III Platinum® One-Step qRT-PCR Kit (Life Technologies) and run on a 7900HT Thermocycler (Applied Biosystems) for 50 cycles. Results were used only if the EGFP RT-PCR showed a CT value <28 to assure quality of the RNA extraction and PCR reaction. To relatively quantify viral load, RNA obtained from a serially diluted stock of JEV Nakayama with a known titer was used as a standard. To this end, a virus stock with a known infectivity titer was serially diluted in log10 steps and viral RNA extracted. After qRT-PCR, CT values were determined to draw a standard curve, which was linear (correlation coefficient R of 0.998) in the range of 35.6–12.6 CT which corresponded to 1 × 100–1.2 × 107 TCID50/mL of the viral stock. The CT value corresponding to 1 TCID50 was defined as 1 RNA unit (U). Using this standard, the CT values of our samples were then transformed into relative quantities as RNA U/mL. Organ samples were corrected for their weight and data calculated as relative RNA quantities/mg.
To determine infectious virus titers, samples were serially diluted in quadruplicates starting at a dilution of 1:2 (if possible), and 100 μL was added to confluent Vero cells (ATCC, Manassas, VA, USA) cultured in 96-well plates with MEM medium (Life Technologies) containing 1% fetal bovine serum (FBS; Biochrome) and 0.01 M HEPES (Life Technologies). After 4 h, the inoculum was removed, replaced with fresh medium and the cells were incubated for 72 h before fixing them with 4% paraformaldehyde (Polysciences, Warrington, PA, USA) for 10 min and staining with the anti-flavivirus E protein monoclonal antibody 4G2 (HB-112™ ATCC) in saponin (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) followed by horseradish peroxidase conjugated rabbit anti-mouse antibody (Dako, Baar, Switzerland). The final color reaction was obtained by adding 3-amino-9-ethylcarbazole (AEC) (Sigma-Aldrich). Titers were calculated using the Reed and Munch formula. The theoretical detection limit of the virus titration was around 5 TCID50/mL.
For histopathological evaluation organ samples and cross-sectioned blocks of representative areas of the CNS (medulla oblongata, pons, cerebellum, midbrain, thalamus, basal nuclei, olfactory bulb, hippocampus, cerebral cortex and spinal cord were embedded in paraffin, cut at 4 µm and stained with hematoxylin and eosin (HE).
Lesions in the CNS were semi-quantitatively scored from 0 to 4 (0 = no lesions, 1 = minimal lesions, 2 = mild lesions, 3 = moderate lesions, 4 = severe lesions). The scores were based on the number of lesions, the type including perivascular cuffs, neuronal necrosis, glial nodules and parenchymal infiltration by inflammatory cells, as well as size of lesions. Grade 1 was attributed to the presence of single thin perivascular cuffs only or focal small glial nodule. Grade 2 included few perivascular cuffs and few glial nodules. Grade 3 was characterized by prominent perivascular cuffs and multiple dense glial nodules with clear neuronal degeneration and neuronophagia (as exemplified in Figure 4). Grade 4 was characterized by extended lesions with prominent perivascular cuffs and numerous glial nodules, that may coalesce, and frequent evidence of neuronophagia. Three healthy, non-infected pigs from the IVI SPF facility were employed as negative controls.
For plaque reduction neutralization tests (PRNT) sera were diluted in medium in triplicates starting at 1:5 and twofold serially diluted to a dilution of 1:640. One hundred plaque forming units (PFU)/well of homologous virus were added to each well followed by gentle agitation and incubation at 37 °C for 30 min. Confluent Vero cells in flat bottom 96 well plates (Corning, Sigma Aldrich) were then incubated with 25 µL of the serum-virus mix for 1 h at 37 °C before washing with warm MEM medium (as above) and adding 200 µL of 1% methylcellulose (Sigma-Aldrich) medium supplemented with 100 IU penicillin and 100 µg/mL streptomycin at 200 µL/well. After incubation for 48 h at 37 °C, the cells were fixed and stained as described above. PRNT50 titres were read as the last serum dilution that showed a reduction of the counted PFU by 50%.
Serum prepared from blood samples was analyzed for interferon-α (IFN-α), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) using commercial porcine cytokine ELISA kits (R&D Systems, Abingdon, UK) according to manufacturer’s instructions.
Statistical analysis was done with GraphPad Prism (GraphPad Software, La Jolla, USA) using ANOVA and Mann–Whitney U test to calculate group differences. Significance level was set at 5%.
The three pigs sampled for blood daily showed a prominent viremia in terms of viral RNA with a peak at day one pi and a viral RNA load of around 10 000 RNA U/mL (Figure 1B). Based on a standard curve performed, one RNA U corresponds to 1 TCID50 infectious virus. Viremia decreased gradually by 1–2 logs10 per day until day 4 pi. Sera from animals slaughtered on day 3 pi still showed a viremia above the threshold of the real-time RT-PCR with relative RNA quantities of 10 units/mL of serum. On day 5 all pigs were below cut-off of the RT-PCR. To determine how viral RNA levels correlate to live virus detection by cell culture we titrated some of the sera. As shown in Figure1C, a comparable kinetic was found with three representative sera from the animals bled daily. In contrast to the serum, no viral RNA was detected in PBMC.
Oro-nasal excretion of JEV
Interestingly, we were able to detect viral RNA and live virus in oro-nasal swabs collected from the three animals which were kept until day 11. As shown in Figure 1D, this was found between 2 and 8 days pi, depending on the animal.
Virus tropism for non-CNS tissue
Virus isolation data from tonsils
3.14 × 104
3.16 × 105
3.16 × 105
1.47 × 103
3.16 × 105
3.14 × 104
3.16 × 105
1.00 × 104
1.78 × 104
4.39 × 102
6.81 × 104
3.16 × 103
Virus tropism for CNS tissue
To determine if JEV induced an early systemic inflammatory response, serum obtained from the daily blood samples was analyzed by ELISA for IFN-α, IL-1β, IL-6 and TNF-α. In none of the samples cytokines levels above those of non-infected healthy pigs were found (data not shown).
Within the last two decades several vector borne viral diseases have emerged in Europe [19, 20]. The observation that JEV RNA was found in Culex pipiens in Italy represents a warning, although this was only described in one study . In terms of mosquito vectors Culex and Aedes species, which can potentially transmit JEV, are present in southern Europe up to the south of Switzerland . Considering that some areas in Europe have intensive pig farming, introduction of JEV could potentially result in severe health and socio-economical consequences. Pigs are considered to be the main amplifying host and important reservoirs along with water birds. In order to estimate the risk of a potential emergence of JEV into the Western hemisphere, it is important to know if local breeds of pigs are susceptible to viral infection, and in particular if they develop a viremia to a duration and magnitude comparable to Asian breeds of pigs. Our study indicates that this is the case at least with Swiss Large White pigs. The clinical signs observed were comparable to findings of previous reports with fever of between 40 and 41 °C for 3–5 days, with highest body temperatures beyond the end of the viremia. This was associated with decreased appetite, awareness and depression. The observed symptoms were possibly caused by the viral encephalitis and not by a virally induced systemic inflammation [14, 15]. With our infection model, viremia lasted for 2–4 days with the peak at day 1 pi. This was comparable to the study of Sasaki and colleagues in which the pigs were viremic from day 1 to 4 pi using mosquito bite and subcutaneous injection . Other studies also found a viremia of 1–3 days duration occurring between day 1 and 5 pi [24, 25].
As in none of the previously published studies viral loads in various tissues were determined, the viral tropism of JEV in the CNS and non-CNS tissue of pigs required investigations. For this reason, we performed real-time RT-PCR in various tissues collected from serially slaughtered pigs. Our data indicate that in the bone marrow, thymus, kidney, liver and skeletal muscle, the virus is not present much longer than the viremia is lasting, although individual variations were observed. In contrast, in the brain, as well as in secondary lymphoid tissue including spleen, lymph node and in particular the tonsils virus was detectable clearly beyond the viremic phase. As for the ileum, which had comparable viral RNA loads to the lymph nodes, we collected the terminal part containing the continuous Peyer’s patches. We speculate that also in this organ the site of virus replication is in lymphoid tissue. Altogether, our data indicate that the virus has a relatively broad tissue tropism with a preference for nervous and lymphoid tissues. Nevertheless, although PBMC can be infected in vitro [26, 27], PBMC isolated from infected animals remained negative in the RT-PCR throughout the experiment. Future in vitro and in vivo studies are now required to determine the cellular tropism of JEV in pigs. Especially lymphoid tissue will be of large interest.
Although clinical signs were mild and no clear neurological deficits were observed, all animals were affected by non-suppurative meningoencephalomyelitis. Lesions in most brain regions appeared at day 3 and persisted until day 11 pi. The spinal cord and cerebellum were affected from day 5 on. Lesions and their distribution were similar to JEV-meningoencephalomyleitis previously described in experimental intravenous infections of pigs and macaques [14, 15, 28] and in natural infections of human [29–31]. Similar to these studies, we found neuronal degeneration and necrosis confirming a neurotropism of the JEV strain used [14, 15, 28]. Although the olfactory bulb appeared to be slightly stronger affected than other CNS regions at day 3, the widely disseminated distribution of lesions was compatible with a hematogenous virus entry into the CNS , possibly by free virus particles during the viremic phase as indicated by our serum RT-PCR results. The absence of JEV in PBMC indicate that these cells do not function as Trojan horses for JEV entry into the CNS as it has been described for other viruses [32, 33]. As described in mice JEV entry into the CNS via the blood-cerebrospinal fluid barrier appears to be unlikely as neither viral RNA or lesions were observed in the choroid plexus nor in ependymal or periventricular tissue . Future studies also need to consider alternatives routes of viral entry into the CNS, such as transneural virus transport, which may occur for example from the olfactory nerve to the olfactory bulb from which the virus may further spread to the CNS as has been described for other neurotropic flaviviruses (for review see ). This may link virus replication in the tonsils with spread to the CNS.
The most striking novel observations in terms of JEV tropism were found in the tonsils, in which JEV appeared to continue its replication for at least 11 days. This was 6 days after the end of viremia and the onset of neutralizing antibody responses. In addition, viral loads were 100–1000 times higher compared to other organs. Only in one previous study, JEV was isolated from the tonsil of a pig  but to our knowledge, viral infection of the tonsils in pigs or other species has not been described. It should be noted that the present study employed a high dose of JEV (107 TCID50/animal), which could theoretically result in a different tissue distribution as a natural infection. However, although we do not have samples from naturally infected pigs available, data from several pigs infected with doses of JEV as low as 103 TCID50/animal via the oro-nasal route resulted in a comparable tissue distribution. Again, the highest viral loads are also found in the tonsils . This suggests that although the kinetic of the infection and the incubation time may vary, the virus distribution reported here is relevant for the field situation.
Future studies are required to determine how long the virus can persist in pigs as a long-term persistence could have an important impact on the ecology of JEV in temperate regions. In fact, for recurrent JEV outbreaks observed in particular farms in consecutive years in Hokkaido, the mechanisms of hibernation of JEV remain unclear [6, 37]. Although experimentally JEV can transmit vertically in Culex mosquitoes [38, 39], it has been very difficult to find infected mosquito larvae in the field .
Previous studies indicate that neutralizing antibodies are important for protection against JEV with a protective neutralizing titer of 10, in both humans and in pigs [25, 41–43]. Our study confirms that the immune system of pigs efficiently and rapidly reacts to JEV infection. Within one weak pi, similar levels of neutralizing antibodies are reached as compared with a live attenuated vaccine  conferring protective immunity. Under our experimental conditions JEV did not induce systemic inflammatory cytokine response also supporting a rapid control of virus replication.
Taken together this study demonstrates that after experimental infection of pigs JEV rapidly and broadly spreads to the CNS and various organs outside the CNS. It appears that the secondary lymphoid tissue plays a prominent role in virus replication with the tonsils being a predilection site for JEV in terms of both viral loads and duration of replication. Considering the important role of pigs in the ecology of JEV, future investigations are required to understand virus-host interactions at the level of the organism and the cell.
The authors declare that they have no competing interests.
MER design of the study, data acquisition and analysis, drafting the manuscript. OGN data analysis, critically reviewing the manuscript. DB design of the study, data acquisition. SP data acquisition, data analysis. BZ data acquisition, data analysis. HP design of the study, data acquisition, data analysis. AO data acquisition, data analysis, critically reviewing the manuscript. AS design of the study, data acquisition, data analysis, finalizing manuscript. All authors read and approved the final manuscript.
We thank the biosafety team for valuable support in planning and conducting the animal experimentation and laboratory work requiring BSL3 conditions.
This work was supported by European Union’s Seventh Framework Program for research, technological development and demonstration under Grant Agreement No. 278433-PREDEMICS.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Impoinvil DE, Baylis M, Solomon T (2013) Japanese encephalitis: on the one health agenda. Curr Top Microbiol Immunol 365:205–247PubMedGoogle Scholar
- van den Hurk AF, Ritchie SA, Mackenzie JS (2009) Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev Entomol 54:17–35View ArticlePubMedGoogle Scholar
- Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai TF, Tsu VD, Ginsburg AS (2011) Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ 89:766–774PubMed CentralView ArticlePubMedGoogle Scholar
- Weaver SC, Barrett AD (2004) Transmission cycles, host range, evolution and emergence of arboviral disease. Nat Rev Microbiol 2:789–801View ArticlePubMedGoogle Scholar
- Endy TP, Nisalak A (2002) Japanese encephalitis virus: ecology and epidemiology. Curr Top Microbiol Immunol 267:11–48PubMedGoogle Scholar
- Takashima I, Watanabe T, Ouchi N, Hashimoto N (1988) Ecological studies of Japanese encephalitis virus in Hokkaido: interepidemic outbreaks of swine abortion and evidence for the virus to overwinter locally. Am J Trop Med Hyg 38:420–427PubMedGoogle Scholar
- Scherer WF, Moyer JT, Izumi T, Gresser I, Mc CJ (1959) Ecologic studies of Japanese encephalitis virus in Japan. VI. Swine infection. Am J Trop Med Hyg 8:698–706PubMedGoogle Scholar
- Hurlbut HS, Thomas JI (1950) Observations on the experimental transmission of Japanese encephalitis by mosquitoes. Am J Trop Med Hyg 30:683–688PubMedGoogle Scholar
- Scherer WF, Moyer JT, Izumi T (1959) Immunologic studies of Japanese encephalitis virus in Japan. V. Maternal antibodies, antibody responses and viremia following infection of swine. J Immunol 83:620–626PubMedGoogle Scholar
- Le Flohic G, Porphyre V, Barbazan P, Gonzalez JP (2013) Review of climate, landscape, and viral genetics as drivers of the Japanese encephalitis virus ecology. PLoS Negl Trop Dis 7:e2208PubMed CentralView ArticlePubMedGoogle Scholar
- Hurlbut HS (1964) The pig-mosquito cycle of Japanese encephalitis virus in Taiwan. J Med Entomol 1:301–307View ArticlePubMedGoogle Scholar
- Burns KF (1950) Congenital Japanese B encephalitis infection of swine. Proc Soc Exp Biol Med 75:621–625View ArticlePubMedGoogle Scholar
- Liu H, Lu HJ, Liu ZJ, Jing J, Ren JQ, Liu YY, Lu F, Jin NY (2013) Japanese encephalitis virus in mosquitoes and swine in Yunnan province, China 2009–2010. Vector Borne Zoonotic Dis 13:41–49PubMed CentralView ArticlePubMedGoogle Scholar
- Yamada M, Nakamura K, Yoshii M, Kaku Y (2004) Nonsuppurative encephalitis in piglets after experimental inoculation of Japanese encephalitis flavivirus isolated from pigs. Vet Pathol 41:62–67View ArticlePubMedGoogle Scholar
- Yamada M, Nakamura K, Yoshii M, Kaku Y, Narita M (2009) Brain lesions induced by experimental intranasal infection of Japanese encephalitis virus in piglets. J Comp Pathol 141:156–162View ArticlePubMedGoogle Scholar
- Rau H, Revets H, Balmelli C, McCullough KC, Summerfield A (2006) Immunological properties of recombinant classical swine fever virus NS3 protein in vitro and in vivo. Vet Res 37:155–168View ArticlePubMedGoogle Scholar
- Hoffmann B, Depner K, Schirrmeier H, Beer M (2006) A universal heterologous internal control system for duplex real-time RT-PCR assays used in a detection system for pestiviruses. J Virol Methods 136:200–209View ArticlePubMedGoogle Scholar
- Yang DK, Kweon CH, Kim BH, Lim SI, Kim SH, Kwon JH, Han HR (2004) TaqMan reverse transcription polymerase chain reaction for the detection of Japanese encephalitis virus. J Vet Sci 5:345–351PubMedGoogle Scholar
- Mackenzie JS, Gubler DJ, Petersen LR (2004) Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10:S98–109View ArticlePubMedGoogle Scholar
- Zeller H (2012) Is Japanese encephalitis emerging in Europe? Euro Surveill 17:20242PubMedGoogle Scholar
- Ravanini P, Huhtamo E, Ilaria V, Crobu MG, Nicosia AM, Servino L, Rivasi F, Allegrini S, Miglio U, Magri A, Minisini R, Vapalahti O, Boldorini R (2012) Japanese encephalitis virus RNA detected in Culex pipiens mosquitoes in Italy. Euro Surveill 17:20221PubMedGoogle Scholar
- Platonov A, Rossi G, Karan L, Mironov K, Busani L, Rezza G (2012) Does the Japanese encephalitis virus (JEV) represent a threat for human health in Europe? Detection of JEV RNA sequences in birds collected in Italy. Euro Surveill 17:20241PubMedGoogle Scholar
- Sasaki O, Karoji Y, Kuroda A, Karaki T, Takenokuma K, Maeda O (1982) Protection of pigs against mosquito-borne Japanese encephalitis virus by immunization with a live attenuated vaccine. Antiviral Res 2:355–360View ArticlePubMedGoogle Scholar
- Williams DT, Daniels PW, Lunt RA, Wang LF, Newberry KM, Mackenzie JS (2001) Experimental infections of pigs with Japanese encephalitis virus and closely related Australian flaviviruses. Am J Trop Med Hyg 65:379–387PubMedGoogle Scholar
- Imoto J, Ishikawa T, Yamanaka A, Konishi M, Murakami K, Shibahara T, Kubo M, Lim CK, Hamano M, Takasaki T, Kurane I, Udagawa H, Mukuta Y, Konishi E (2010) Needle-free jet injection of small doses of Japanese encephalitis DNA and inactivated vaccine mixture induces neutralizing antibodies in miniature pigs and protects against fetal death and mummification in pregnant sows. Vaccine 28:7373–7380View ArticlePubMedGoogle Scholar
- Sapkal GN, Wairagkar NS, Ayachit VM, Bondre VP, Gore MM (2007) Detection and isolation of Japanese encephalitis virus from blood clots collected during the acute phase of infection. Am J Trop Med Hyg 77:1139–1145PubMedGoogle Scholar
- Sooryanarain H, Sapkal GN, Gore MM (2012) Pathogenic and vaccine strains of Japanese encephalitis virus elicit different levels of human macrophage effector functions. Arch Virol 157:1905–1918View ArticlePubMedGoogle Scholar
- Myint KS, Kipar A, Jarman RG, Gibbons RV, Perng GC, Flanagan B, Mongkolsirichaikul D, Van Gessel Y, Solomon T (2014) Neuropathogenesis of Japanese encephalitis in a primate model. PLoS Negl Trop Dis 8:e2980PubMed CentralView ArticlePubMedGoogle Scholar
- Solomon T, Dung NM, Kneen R, Gainsborough M, Vaughn DW, Khanh VT (2000) Japanese encephalitis. J Neurol Neurosurg Psychiatry 68:405–415PubMed CentralView ArticlePubMedGoogle Scholar
- Solomon T (2004) Flavivirus encephalitis. N Engl J Med 351:370–378View ArticlePubMedGoogle Scholar
- Solomon T, Vaughn DW (2002) Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Curr Top Microbiol Immunol 267:171–194PubMedGoogle Scholar
- Peluso R, Haase A, Stowring L, Edwards M, Ventura P (1985) A Trojan Horse mechanism for the spread of visna virus in monocytes. Virology 147:231–236View ArticlePubMedGoogle Scholar
- Williams KC, Corey S, Westmoreland SV, Pauley D, Knight H, deBakker C, Alvarez X, Lackner AA (2001) Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. J Exp Med 193:905–915PubMed CentralView ArticlePubMedGoogle Scholar
- Li F, Wang Y, Yu L, Cao S, Wang K, Yuan J, Wang C, Wang K, Cui M, Fu ZF (2015) Viral infection of the central nervous system and neuroinflammation precede blood-brain barrier disruption during Japanese encephalitis virus infection. J Virol 89:5602–5614PubMed CentralView ArticlePubMedGoogle Scholar
- Suen WW, Prow NA, Hall RA, Bielefeldt-Ohmann H (2014) Mechanism of West Nile virus neuroinvasion: a critical appraisal. Viruses 6:2796–2825PubMed CentralView ArticlePubMedGoogle Scholar
- Ricklin EM, Garcia-Nicolas O, Brechbühl D, Python S, Zumkehr B, Nougairede A, Charrel NR, Posthaus H, Oevermann A, Summerfield A. Vector-free transmission and persistence of Japanese encephalitis virus in pigs. Nat Commun, in press
- Rosen L (1986) The natural history of Japanese encephalitis virus. Annu Rev Microbiol 40:395–414View ArticlePubMedGoogle Scholar
- Rosen L, Tesh RB, Lien JC, Cross JH (1978) Transovarial transmission of Japanese encephalitis virus by mosquitoes. Science 199:909–911View ArticlePubMedGoogle Scholar
- Rosen L, Lien JC, Shroyer DA, Baker RH, Lu LC (1989) Experimental vertical transmission of Japanese encephalitis virus by Culex tritaeniorhynchus and other mosquitoes. Am J Trop Med Hyg 40:548–556PubMedGoogle Scholar
- Rosen L, Lien JC, Lu LC (1989) A longitudinal study of the prevalence of Japanese encephalitis virus in adult and larval Culex tritaeniorhynchus mosquitoes in Northern Taiwan. Am J Trop Med Hyg 40:557–560PubMedGoogle Scholar
- Oya A (1988) Japanese encephalitis vaccine. Acta Paediatr Jpn 30:175–184View ArticlePubMedGoogle Scholar
- Hombach J, Solomon T, Kurane I, Jacobson J, Wood D (2005) Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004. Vaccine 23:5205–5211View ArticlePubMedGoogle Scholar
- Van Gessel Y, Klade CS, Putnak R, Formica A, Krasaesub S, Spruth M, Cena B, Tungtaeng A, Gettayacamin M, Dewasthaly S (2011) Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO((R))) induced neutralizing antibody titers. Vaccine 29:5925–5931View ArticlePubMedGoogle Scholar